Medable has deployed its software-as-a-service platform across more than 300 decentralized and hybrid clinical trials in 60 countries, putting it at the forefront of efforts to shift studies from sites to homes. The California-based company expects to benefit from applying the platform to GSK clinical trials.
“As a key partner, Medable will benefit from collaborating with one of the leading innovators in the pharmaceutical industry with a global footprint and the resources to invest in further development and refinement of the decentralized clinical trial model,” said Michelle Longmire, co-founder and CEO at Medable. “Together, we will continue to evolve DCTs to improve patient access, efficiency, data quality, and population representation in research.”
Information about how the relationship will work and exactly what it will mean for Medable are thin on the ground, with the statement to disclose the news lacking such key details and Longmire sidestepping questions on the topics.
Even so, the deal points to the growing commitment to hybrid and decentralized clinical trials, both at GSK and in the wider industry. Having initially tried out the model on a trial-by-trial basis, GSK has now reached the point in its adoption of the approach that a four-year, preferred partner deal makes sense.
To win share in the nascent market, Medable is building out its offering in certain areas, including some such as vaccines and oncology that overlap with the therapeutic areas of focus at GSK.
“Medable recently announced its new Vaccine Offering – a vaccine DCT in a box – that templatizes some common elements of standing up a vaccine trial, cutting startup time in half, from an average of 12-plus weeks to less than five. Medable is also enhancing many of its applications, including its consenting solution and applications specific to therapeutic areas such as oncology,” said Longmire.